Prostatic Urethral Lift

Anatomy and Physiology

The prostate gland is a robust fibromuscular structure with an inverted cone shape; its base surrounds the bladder neck inferiorly, while its apex is at the external urethral sphincter.[8] Anterior to the prostate is the pubic symphysis, separated by a fatty pad and the prostatic venous plexus. Posteriorly, Denonvillier fascia delineates the boundary with the rectum. The external urethral sphincter below the gland plays a crucial role in urinary continence and facilitating ejaculatory flux. The levator ani muscles, situated laterally, are close to the prostate.[9]

Structurally, the prostate is partitioned into 5 distinct lobes: anterior, posterior, 2 lateral lobes, and a median lobe.[10] Regarding zonal anatomy, the central zone constitutes the base, enveloping the ejaculatory ducts, while the peripheral zone is the largest, accounting for 70% of the prostate's central area and partially encasing the distal prostatic urethra. The transition zone, albeit smaller, is glandular and surrounds the urethra from the bladder neck to the verumontanum. The anterior fibromuscular stroma, devoid of glandular tissue, enfolds the apex of the prostate. A fibrous capsule entirely encases the prostate, providing an anatomical boundary.[11]

BPH is characterized by nodular hyperplasia, primarily affecting the prostate's transition (lateral lobes) and central (median lobe) zones.[5] This hyperplasia often takes the form of multiple nodules, with those arising from the transition zone giving rise to the lateral lobes and those from the central zone forming the median lobe. When BPH results in urinary outflow obstruction, it is mainly due to the distortion of the urethral anatomy rather than direct compression of the bladder outlet.[12]

Indications

The primary modality for the management of BPH is pharmacotherapy, typically commencing with alpha-adrenergic receptor antagonists, which may be prescribed singularly or in combination with 5 alpha-reductase inhibitors.[13] In instances where a patient presents with persistent symptomatology that is recalcitrant to initial pharmacological interventions, exhibits intolerance to the adverse effects of these medications, or elects to pursue therapy with greater durability and efficacy, alternative therapeutic strategies may be warranted.[5]

BPH involves the formation of nodular hyperplasia predominantly in the prostate gland's transition (lateral lobes) and central (median lobe) zones. This condition typically manifests as numerous nodules, which in the transition zone contribute to the enlargement of the lateral lobes and, in the central zone, lead to the growth of the median lobe. In cases where BPH obstructs urinary outflow, it is primarily due to the alteration of urethral anatomy instead of the outright compression of the bladder outlet.[5] The enlargement of the lateral lobes of the prostate is commonly implicated in the pathogenesis of LUTS, establishing a criterion for patient selection.[4]

Minimally Invasive Surgical Interventions for Benign Prostate Hyperplasia

Surgical modalities that serve as potential therapeutic alternatives for relieving persistent LUTS include:

• Conventional endoscopic ablative methods such as transurethral resection of the prostate (TURP), GreenLight laser™ photovaporization (GLL-PVP), and holmium laser enucleation of the prostate (HoLEP) are options.
• Radical open surgical techniques like the simple (Millin) prostatectomy are potential therapies.
• Interventional radiology approaches encompass prostatic artery embolization (PAE) as an alternative therapy option.
• Minimally invasive interventions include PUL, water vapor thermal ablation of the prostate (WVAP), the Optilume BPH system, and the deployment of a temporary nitinol device.

Selecting the most suitable treatment strategy requires a thorough evaluation of multiple criteria: the patient's personal preferences and objectives, the comorbidities present and the overall risk profile of the patient, the dimensions and anatomical structure of the prostate, as well as a comprehensive analysis of the risks and potential advantages associated with each surgical option.[5]

PUL

PUL stands out as a targeted treatment modality for BPH, particularly in patients manifesting significant LUTS that adversely affect their quality of life.[4][14] Candidates for PUL ideally possess a normal bladder neck and exhibit only minimal enlargement of the prostate's median lobe. While historically, the presence of an obstructive median lobe was regarded as a contraindication to treatment, hence its role as a criterion for exclusion in the L.I.F.T study, subsequent findings from the MedLift study have demonstrated that obstructive median lobes can be effectively addressed using the prostatic urethral lift technique, yielding comparable results.[15]

Recent investigations targeting patients with prominent median lobes undergoing TURP have indicated that individuals with a significant median lobe protrusion into the bladder of 10 mm or more may derive marked benefit from therapeutic interventions targeting this specific form of obstruction. The PUL method has been shown to be efficacious independent of the overall prostatic volume or the extent of intravesical prostatic protrusion (IPP), with this efficacy sustained over a 2-year follow-up period.[16] Within 1 month postprocedure, 86% of patients reported significant alleviation of symptoms, alongside notable enhancements in maximum urinary flow rate (Qmax), postvoid residual volume (PVR), international prostate symptom score (IPSS), and quality of life measures, with statistical significance (P <0.001).[16]

Additionally, data from studies have been documented over a period extending to 5 years, indicating the procedure is optimal for individuals whose prostate volume measures between 20 to 100 cm³.[3][17] Residual volumes should ideally not be at significant extremities; however, it has been demonstrated to be effective in volumes between 44 to 488 mL with an average reduction of 139.7 mL.[18]

The preservation of sexual function is a paramount concern, especially for younger men who may be hesitant about treatments that potentially compromise erectile or ejaculatory capabilities. Encouragingly, results from studies, such as a notable investigation in Australia, have demonstrated that the PUL procedure does not detrimentally affect sexual function postoperatively.[2] Sexual and ejaculatory function was also maintained in individuals who had undergone PUL with an obstructive median lobe.[16] This benefit makes PUL a favorable option for those who are reluctant to commence or continue lifelong medication for LUTS or for patients whose symptoms are not adequately managed by medical therapy and who are seeking surgical intervention.

Inclusion criteria for PUL include the following: 

• Age >50 years
• Prostate volume of 20 to 100 cm³
• IPSS >12
• Qmax <15 mL/s
• PVR <350 mL [19]

Concerning prostatic morphology once deemed a contraindication in cases of obstructive median lobes, recent evidence suggests otherwise, proposing that with precise surgical approaches, symptoms can be alleviated for a minimum of 2 years.[3] The preservation of erectile and ejaculatory functions has been noted.[16] The adverse events reported were generally mild and of a short-term nature. Symptomatic relief was observed as early as 2 weeks postprocedure and has been shown to persist for up to 5 years.[20][21] The retreatment rate is 6% annually among patients who have previously undergone such interventions. Of these patients, 51% underwent traditional endoscopic removal methods like TURP or laser enucleation of the prostate. In contrast, 32.7% received a secondary PUL, and 20% had a PUL device removal.[22]

Water Vapor Thermal Ablation of the Prostate

This procedure entails the injection of heated water vapor at 103 °C into the prostatic tissue, leading to immediate cellular death and creating an ablated lesion through apoptosis over 6 to 12 months.[23] Results from longitudinal studies have observed outcomes spanning up to 5 years. Water vapor thermal ablation of the prostate is applicable for prostatic volumes ranging from 30 to 100 cm³ and is effective across a spectrum of prostatic morphologies, including cases with median lobe enlargement.[23][24] The ejaculatory function remains unaltered postprocedure.[23][25] Patients report minimal and short-lived side effects. Initial symptomatic improvement is observed within 4 weeks, with full benefits accruing up to 12 months and sustainability of up to 5 years.[26] The rate of retreatment at the 5-year mark stands at 4.4%.[26]

Optilume Benign Prostatic Hyperplasia Catheter System

The Optilume benign prostatic hyperplasia (BPH) catheter system uses a dual-lobe balloon for the mechanical expansion of the prostatic fossa and delivers paclitaxel to deter further tissue growth.[27] Data reflecting outcomes are accessible up to 2 years postprocedure.[27][28] The Optilume BPH catheter system is designed for prostate sizes within the 20 to 80 cm³ range but is not recommended for cases with significant median lobe obstructions. The ejaculatory function is preserved. Side effects are typically mild and fleeting; symptom relief commences at 3 months, persisting for a year, as supported by the published data.[29]

iTind Device

The iTind device involves a temporary implant with nitinol struts that expand gradually over 5 to 7 days, exerting outward triangular force and inducing ischemia and subsequent necrosis for prostatic tissue remodeling.[30] Study findings are reported up to 2 years following implantation.[31] The advised prostate volume for this treatment is between 25 to 75 cm³, and it is not indicated for patients with median lobe enlargement, which was observed to have higher treatment failure rates.[31] The ejaculatory function is maintained. The intervention is associated with minor and transient adverse effects. Relief from symptoms typically begins within 3 months, lasting up to a year. The retreatment rate at 2 years is 14.8%.[31]

Comparing PUL vs Alternatives

PUL is distinguished by its proven efficacy in symptom alleviation for up to 5 years, as recorded in the current literature. PUL can treat a broad range of prostatic sizes and is efficacious for volumes up to 100 cm³. Recent advancements in surgical techniques render median lobe enlargement a manageable condition rather than a contraindication for PUL. The procedure upholds normal ejaculatory functions. Symptom relief is instantaneous, surpassing other minimally invasive techniques such as water vapor thermal ablation of the prostate (WVAP). For patients with notable comorbidities and higher anesthetic risks, PUL offers a minimal risk profile and can be performed in an outpatient setting with local anesthesia within approximately 10 to 15 minutes. Postoperative catheterization is less frequently necessitated with PUL.

PUL and WVAP are among the most thoroughly researched and established minimally invasive techniques for managing symptomatic BPH. PUL, in particular, has been associated with more rapid symptom improvement and long-lasting effects. Comparatively, patient-reported outcomes post-PUL exhibit significantly better IPSS and quality-of-life metrics than that post-WVAP.[32] Notably, patients with PUL have a markedly lower catheterization rate by the third postoperative day than patients with WVAP; 7% of patients who underwent PUL were catheterized by postoperative day 3 compared to 55% of patients with WVAP.[32] Furthermore, patients with PUL report significantly higher sexual health inventory for men (SHIM) scores, indicative of better sexual function.[32] Thus, PUL is superior in several respects, including sexual health, reduced catheterization rates, greater patient satisfaction, and minimal disruption to daily activities.

Contraindications

Based on scientific data, PUL is contraindicated in several specific situations and patient conditions. Individuals with a recent history of prostatitis within the past year or who have active urinary tract infections are not considered suitable candidates due to the potential for exacerbating inflammation and infection. Those with a history of urinary retention or who have undergone previous surgical interventions for benign BPH might have altered anatomy or scar tissue that could complicate the PUL procedure. Similar concerns apply to patients who have had prior pelvic surgery or irradiation, as these factors may alter pelvic anatomy or compromise tissue integrity, thereby increasing the risk of complications.[2][15][33][34] A prostate-specific antigen (PSA) level greater than 10 ng/mL is also a contraindication unless a negative biopsy has confirmed the absence of prostate cancer.[2][19][33][35]

In addition to these specific patient factors, the PUL system has limitations that might contraindicate its use in certain patients. Technical challenges may arise in individuals with a high bladder neck. PUL is also contraindicated for patients with significantly enlarged prostates (greater than 100 mL).[1][2][35][36] The lack of studies demonstrating long-term data and research on patients with multiple comorbidities further limits the procedure's suitability. Prospective patients should also be aware of the potentially high retreatment rate in the long term and the high cost per implant, which might influence their decision to proceed with PUL.[37]

The exclusionary criteria are summarized below:

• Acute urinary tract infection
• PSA >10 ng/ml (unless negative biopsy)
• Prostatitis within the past year
• History of urinary retention
• Previous BPH procedure
• Previous pelvic surgery or irradiation

Equipment

The following equipment is essential to performing PUL: 

• 2.9 mm 0° scope
• 20F sheath 
• Visual obturator 
• Cystoscopy camera and monitoring equipment
• Fluid irrigation system
• Standard endoscopic grasper kit
• Lidocaine infused lubrication
• Prostatic urethral device (see Image. Prostatic Urethral Device)

Keeping a grasper kit or a similar urological instrument designed for extracting foreign objects on hand is advised if removing or retrieving a part of the PUL implant during surgery becomes essential.

The following equipment is optional when performing PUL: 

• Two-way Foley catheter and drainage bag
• Transrectal ultrasound for local prostatic anesthesia
• Local anesthetic and appropriate needle for injection

Personnel

The following personnel are needed to perform PUL:

• Surgeon
• Scrub nurse
• Circulating nurse
• Anesthesia team

Preparation

History

An exhaustive clinical history focused on the patient's LUTS is imperative, encompassing symptoms such as incomplete bladder emptying, frequency, urgency, intermittency, straining, and nocturia. Concomitant symptoms, including dysuria, hematuria, incontinence, and previous urinary calculi, must be meticulously documented. Prior medical or surgical interventions targeting LUTS, including alpha-blockers and 5-alpha reductase inhibitors, should be scrutinized.

A baseline International Prostate Symptom Score or American Urological Association (AUA) BPH symptom score is an invaluable benchmark.[38] The IPSS is an 8-item quantitative instrument designed for the evaluation, rapid detection, longitudinal monitoring, and stratification of treatment for BPH.[39] Comprised of 7 questions, it directly interrogates the severity of BPH-related LUTS and 1 additional item appraising the patient's perceived quality of life secondary to these symptoms. Responses to the symptom-specific questions are structured as a Likert scale, with the patient selecting from a gradation of responses indicating progressive symptom severity, scored from 0 (absent) to 5 (severe). The aggregate potential score spans from 0, denoting absence of symptoms, to 35, indicating extreme symptomatology.[39] The 7 urinary symptoms evaluated are incomplete bladder emptying, urinary frequency, intermittent urination, urgency, weak urinary stream, straining during urination, and nocturia.

The symptom score is aligned with that of the AUA symptom index, classifying symptoms into 3 categories based on the total score: mild (total symptom score ≤7), moderate (total symptom score range 8-19), and severe (total symptom score range 20–35). A comprehensive history ascertains the primary nature of LUTS (voiding, storage, or mixed) and may indicate an etiology other than BPH, such as a bladder dysfunction unrelated to the prostate.[40]

Additionally, an assessment of baseline health parameters is essential, emphasizing prior medical and surgical history, anesthetic assessments, prior urological procedures, or prostate radiation therapy. Erectile function should be quantified using tools like the International Index of Erectile Function-5 (IIEF-5).[41] Urological risk factors, including tobacco use, occupational exposures, and familial history of BPH or prostate cancer, warrant evaluation. Healthcare professionals must also clearly understand the patient's subjective symptom perception and treatment objectives. The clinician is responsible for providing the patient with shared decision-making and establishing reasonable patient expectations.

Physical Examination

The physical examination for LUTS should entail a digital rectal examination to approximate prostate size and screen for prostate malignancy.[42] Inspection of the external genitalia is vital to identify pathologies such as meatal stenosis, lichen sclerosis, and phimosis, which are critical considerations before cystoscope insertion.

Preoperative Workup

The diagnostic workup for PUL mandates urinalysis with microscopy, culture, and sensitivity to exclude infection or unexplained hematuria. PSA measurement is a crucial screening modality preceding BPH interventions to mitigate the risk of delayed prostate cancer diagnosis. Should PSA levels be elevated, malignancy must be ruled out before performing a PUL.[43]

Uroflowmetric evaluation, including Qmax, post-void residual urine test, and voiding pattern analyses, are essential to ascertain symptom severity and etiology and to monitor therapeutic progress. Though not universally requisite, urodynamic studies are critical when alternative or concurrent pathologies such as detrusor underactivity are suspected, particularly in patients with urinary retention.[44] A renal tract ultrasound provides adequate prostate volume and morphology measurements; this will help identify patients who fit the selection criteria for PUL.[45]

Preoperative flexible cystoscopy is advised for the strategic planning of PUL, evaluating the anatomy from the bladder neck to the verumontanum, the dimensions of the lateral lobes, and the presence of a median lobe or elevated bladder neck. Additionally, this procedure permits retroflexive evaluation of the bladder neck, ureteric orifices, and the degree of intravesical prostatic protrusion. Preoperative flexible cystoscopy can also gauge pain tolerance for those selecting local anesthesia.[46]

Preoperative Anticoagulation Guidelines

Blood thinners should ideally be stopped before the procedure. For new oral anticoagulants, 3 days of preoperative cessation is suitable. Recommencement may also occur 2 to 3 days postoperatively.[47] For clopidogrel, 7 days is sufficient, provided the patient can temporarily cease the antiplatelet medication safely.[47] PUL can be performed while the patient continues on aspirin.

Technique or Treatment

The PUL system comprises a single-use, disposable endoscopic delivery instrument with a pistol-grip design for inserting a prostatic implant. This implant is structured as a pair of anchoring elements joined by a durable, nondegradable suture line. During surgical intervention, the surgeon advances the delivery instrument via the urethra, terminating at the prostatic segment. Deployment of the implant is achieved through the penetration of the prostatic tissue by a slender needle at the instrument's distal end, which then secures an anchor externally to the prostatic capsule. Upon retraction of the needle, tension is applied to the suture, culminating in the fixation of the second anchor within the urethral lumen. The clinical application typically requires approximately 3.5 implants, with the procedural approach adaptable to local or general anesthesia.[17] The patient's care setting for this procedure is flexible; inpatient or outpatient encounters are possible.

Traditional Surgical Technique

The PUL procedure aims to create anterolateral channels in the prostatic fossa above the verumontanum to relieve obstruction. This procedure can be performed using various anesthetic techniques, including local, spinal, or general anesthesia. Lidocaine-infused lubrication jelly is recommended as the most cost-efficient and effective local anesthetic, though other forms may be used. The patient is positioned in lithotomy, and a cystoscopy is performed to assess the bladder neck and the prostate's configuration, focusing on the median and lateral lobes. Ideally, this assessment is completed before the procedure using flexible cystoscopy.

Upon removal of the visual obturator, a 20Fr to 22Fr sheath remains in place. A 0° scope is inserted into the PUL device, and together, they are introduced through the cystoscope sheath. The device's implants are deployed at least 1.5 cm distal to the bladder neck, specifically at 10- or 2-o'clock positions, to prevent the needle from penetrating the bladder neck and base. A suitable gauge for the distal positioning of the implants can be the length measured from the extremity of the instrument to the head of the endoscopic camera.

The procedure involves compressing the lateral lobe at the targeted location by laterally angulating the scope to move the lateral lobe physically. The trigger is then unlocked, and the blue half of the double trigger is pulled in line with the grey trigger (half press), firing a hollow nitinol curved needle through the prostate tissue and its capsule. Care should be taken not to use the camera head as a lever to compress the lobe to avoid incomplete suture deployment. This action delivers a capsular anchor and nylon suture into the prostatic capsule. The operator then retracts the needle (full press), tensions the suture, and advances the instrument towards the bladder neck until a white line appears on the suture. This line indicates proper tension when visualized halfway between the device and the prostate lobe. The button on the back of the PUL device is depressed to deploy the urethral end of the implant and sever the suture. The instrument's tip is then moved to the midline to ensure the urethral anchor is disengaged from the device. Subsequently, the instrument is retracted into the bladder, and the procedure is repeated for both lateral lobes.

After the deployments, the sheath is left within the bladder, and a follow-up cystoscopy is performed to determine if additional implants are necessary to adequately alleviate the obstruction. Implants are distributed along the expanse of each lateral lobe of the prostate, positioning them at intervals of about 1 cm, with corresponding implants on the contralateral sides to achieve the requisite urethra dilation. On average, a patient generally receives 3 to 4 implants. As a maximum guideline, it is advised not to exceed the placement of 10 implants per patient.

Routine PUL in ideal patients does not require catheterization following the procedure. Indications for immediate catheterization following a PUL are catheterization prior to the procedure, overnight stay due to anesthetic concerns, and significant adenomatous bleeding. This methodical approach optimizes the anatomical configuration for improved urinary flow while minimizing invasiveness and preserving erectile and ejaculatory functions.[3]

Updated MEDLIFT Technique for Obstructive Median Lobes

The initial aspect of this updated technique is largely unchanged from the traditional technique. For lateral lobe deployments, the system is angled laterally, 20° to 30°, usually at 10- and 2-o'clock, to compress the anterior third of the obstructive lobe. After addressing the lateral lobes, the obstructive middle lobe should be visualized and assessed with cystoscopy. Rukstalis et al found that, "For middle lobe deployments, the tissue that protrudes intravesically may be pulled into the prostatic fossa and affixed to either side of the urethra dependent on the individual's prostate anatomy. Notably, with large intravesical prostate protusions, not all intravesical tissue needs to be retracted when creating the channel at the bladder neck. Additional tissue may remain intravesical, albeit not obstructing the prostatic fossa." They noted the importance of deploying the implant away from the neurovascular bundles, accomplished by maintaining a deployment trajectory anterior to the 4- and 8-o'clock position when viewing the transverse plane of the urethra as a clock face (See Image. Modified Median Lobe Technique).[15]

Complications

Complications

PUL is associated with a spectrum of potential postoperative complications ranging from minor to major.[48] Patients must be closely monitored postoperatively for these complications to manage them promptly and effectively to ensure patient safety and comfort.

Minor

Minor complications are typically mild, transient, and resolve swiftly. These include:

• Dysuria
• Urinary urgency
• Hematuria
• General discomfort or pelvic pain
• Urinary tract infections [49]

Major

Major complications, while less common, can be more severe. They encompass:

• Clot retention
  • This is the accumulation of blood clots within the bladder, which can obstruct urinary outflow.
• Acute urinary retention
• Urinary incontinence
• Prostatitis
• Epididymo-orchitis [49][50] 
• Breakage of the implant 
  • This is exceedingly rare, with an incidence of 0.004%.[20]

Device-Related 

Complications can arise from the misplacement of the PUL device, which should be positioned at least 1 to 1.5 cm below the bladder neck. If placed too close to the bladder neck, reepithelialization over the nitinol suture may not occur. This can lead to severe irritative symptoms, stone formation adherent to the exposed suture (although stone formation rates are remarkably low at 0.006%), and recurrent urinary tract infections.[20]

Magnetic Resonance Imaging Considerations

Nonclinical evaluations have established that the PUL implant is magnetic resonance image (MRI)-compatible, though conditionally so. Individuals implanted with this device may undergo MRI without adverse effects under the stipulated criteria:

• The static magnetic field must be 3 Tesla or lower.
• Based on extrapolation, the spatial field gradient should not exceed 1,500 Gauss/cm (or 15 Tesla/m).
• The MRI system's reported whole-body average specific absorption rate should be at or below 4 W/kg during 15 minutes of continuous scanning in first-level controlled operating mode. 

With adherence to the above scanning parameters, the PUL implant is predicted to cause a maximum temperature increase of 2.4 °C following a 15-minute continuous scanning session. In nonclinical trials, the PUL implant has been shown to produce an image artifact that extends roughly 15 mm from the device, primarily when subjected to gradient echo pulse sequencing in a 3-Tesla MRI environment.

Compared to the apex, image quality deterioration is disproportionately higher in the transitional zone relative to the peripheral zone and in the base and middle regions. The phenomenon is pronounced in diffusion-weighted imaging when contrasted with T2-weighted and dynamic contrast-enhanced sequences. A prostate imaging quality score of ≤2, indicative of suboptimal imaging, was recorded in 16% to 24% of examinations. The obscuration of the prostatic tissue by the UroLift artifact was significantly more pronounced in diffusion-weighted and dynamic contrast-enhanced imaging than in T2-weighted imaging.[51] Patients considering the PUL procedure should be informed about the potential effects of the implant on the quality of MRI images and the consequent ramifications for image-guided prostate cancer assessments.

Clinical Significance

PUL, a minimally invasive surgical procedure to treat LUTS due to BPH, carries significant clinical relevance:

Symptom Relief

PUL has been demonstrated to provide a swift amelioration of LUTS, significantly improving both urinary flow and patients' quality of life. Data from a systematic review involving approximately 600 patients indicated a pooled improvement in the IPSS ranging from 9.73 to 12.16 over 2 years of follow-up. Moreover, the Qmax exhibited an increase from 3.44 mL/s to 4.26 mL/s.[48] These improvements were observed early on and sustained throughout the 24-month observation period, suggesting the durability of PUL outcomes.[48]

However, it is important to note that these improvements, while significant, were less pronounced than those typically achieved with traditional resective procedures like TURP, GLL-PVP, and HoLEP, which have reported Qmax improvements in the range of 10 to 13 mL/s.[52] A study comparing TURP and PUL demonstrated within the first month following the procedure that 82% of individuals who underwent PUL achieved a positive response on the BPH symptom endpoint, in stark contrast to the 53% response rate observed in patients who had undergone TURP.[53]

Sexual Function Preservation

PUL stands out for its conservative impact on sexual health, exhibiting minimal influence on sexual and ejaculatory functions postoperatively. Clinical investigations, including the evaluation of scores from the male sexual health questionnaire ejaculatory dysfunction (MSHQ-EjD) short form, have noted improvements in sexual function after PUL, with pooled estimates of these enhancements ranging from 0.81 to 1.81 across various follow-up intervals.[48] Further research corroborates these findings, indicating a lack of sexual function decline following the procedure.

In comparative terms, Aquablation, a waterjet-based BPH treatment, has been associated with higher instances of ejaculatory dysfunction, reported in approximately 7.8% to 26.7% of cases.[54] Additionally, traditional TURP has been associated with a significant occurrence of retrograde ejaculation, affecting nearly 47.8% of sexually active patients after the procedure, highlighting the advantageous profile of PUL in maintaining sexual function.[55]

Reduced Recovery Time

Because it's less invasive, the recovery time for the PUL procedure is typically shorter compared to traditional surgical procedures such as TURP or open simple prostatectomy, allowing patients to return to normal activities sooner. Significant contrast was observed in postprocedure catheterization, with approximately 74% of patients with TURP requiring catheter use beyond 24 hours after surgery, compared to only 45% of those treated with PUL.

The average hospital stay postprocedure is shorter for PUL, typically 1 day, compared to nearly 2 days for TURP recipients. Furthermore, the return to preoperative activity levels was more expedient for patients undergoing PUL, averaging 11 days. In contrast, those with a TURP reported an average of 17 days to reach the same activity level.[53]

Safety Profile

PUL has a favorable safety profile with a low risk of serious complications, making it a suitable option even for some patients who may not be candidates for more invasive procedures due to comorbid conditions.

Anesthetic Flexibility

The procedure can be performed under local, spinal, or general anesthesia, providing flexibility based on patient preference and comorbidities.

Reduced Medication Needs

PUL can reduce or eliminate the need for ongoing BPH medications, which may have side effects or be contraindicated in certain patients.

Outpatient Procedure

PUL can often be performed as an outpatient procedure, which is cost-effective and convenient for patients and healthcare systems.

Enhancing Healthcare Team Outcomes

Managing benign prostatic hyperplasia using the prostatic urethral lift system necessitates a synchronized interprofessional team effort to ensure patient-centered care and superior outcomes. Urologists, primary care physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals must collaborate in an informed and cohesive manner, each contributing their skills and expertise. The team's collective understanding of the criteria for PUL, the procedural details, and postoperative management strategies is critical for reducing the morbidity associated with BPH and enhancing patients' quality of life.

A strategic approach is essential, focusing on evidence-based methods to ensure the procedure's effectiveness and minimize complications. This includes comprehensive preoperative evaluations, meticulous execution of the procedure, and diligent postoperative supervision. Ethical considerations are paramount, and the team is responsible for ensuring that patients are fully informed about PUL's advantages and potential risks, thus facilitating informed decision-making. Each healthcare professional has distinct responsibilities: urologists lead the procedure, advanced practitioners and nurses focus on patient education and recovery management, and pharmacists manage medication reviews and postoperative care. Effective communication within the team is crucial to keeping all members updated on the patient's condition and treatment plan. Care coordination, from initial scheduling to follow-up care, is vital and may include additional services like physical therapy or specialist consultations. By integrating their expertise, maintaining open communication, and coordinating care, the healthcare team can significantly improve patient safety and outcomes, enhancing the overall management of BPH with the PUL system.